Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 33, 2024 - Issue 2
Submit an article Journal homepage
1,023
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data

Misako Nagasakaa Department of Medicine, University of California Irvine, Orange, CA, USA;b Department of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USA;c Department of Medicine, St. Marianna University School of Medicine, Kawasaki, JapanCorrespondence[email protected]
View further author information
,
Danielle Brazeld Department of Medicine, Scripps Clinic/Scripps Green Hospital, La Jolla, CA, USAView further author information
&
Sai-Hong Ignatius Oua Department of Medicine, University of California Irvine, Orange, CA, USA;b Department of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA, USAView further author information
Pages 79-84 | Received 17 Aug 2023, Accepted 10 Jan 2024, Published online: 29 Jan 2024

References

  • Katayama R, Gong B, Togashi N, et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun. 2019;10(1). doi: 10.1038/s41467-019-11496-z
  • Drilon A, Chiu C-H, Fan Y, et al. Long-term efficacy and safety of entrectinib in ROS1 fusion–positive NSCLC. JTO Clin Res Rep. 2022;3(6):100332. doi: 10.1016/j.jtocrr.2022.100332
  • Cho BC, Lin J, Camidge DR, et al. Pivotal topline data from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with ROS1+ advanced non-small cell lung cancer (NSCLC). Paper presented at: 34th EORTC-NCI-AACR Symposium; Barcelona, Spain; 2022.
  • Papadopoulos KP, Borazanci E, Shaw AT, et al. U.S. Phase I first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2020;26(18):4785–4794. doi: 10.1158/1078-0432.CCR-20-1630
  • Ou SI, Fujiwara Y, Shaw AT, et al. Efficacy of taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: an updated pooled analysis of US and Japan phase 1 studies. JTO Clin Res Rep. 2020;2(1):100108. doi: 10.1016/j.jtocrr.2020.100108
  • Li W, Yang N, Li K, et al. Updated efficacy and safety of taletrectinib in patients with ROS1-positive non-small cell lung cancer (NSCLC). Oral presentation at the European Lung Cancer Congress 2023; Copenhagen, Denmark.
  • Perol M, Yang N, Choi C-M, et al. 1373P efficacy and safety of taletrectinib in patients (pts) with ROS1+ non-small cell lung cancer (NSCLC): interim analysis of global TRUST-II study. Ann Oncol. 2023;34(Supplement 2):S788–S789. doi: 10.1016/j.annonc.2023.09.2406
  • Shaw AT, SHI O, Bang YJ, et al. Crizotinib in ROS1 -rearranged non–small-Cell lung cancer. N Engl J Med. 2014;371(21):1963–1971. doi: 10.1056/NEJMoa1406766
  • Wu YL, Yang JCH, Kim DW, et al. Phase II study of crizotinib in east asian patients with ROS1-positive advanced non–small-Cell lung cancer. J Clin Oncol. 2018;36(14):1405–1411. doi: 10.1200/JCO.2017.75.5587
  • Gainor JF, Tseng D, Yoda S, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1 -positive non–small-Cell lung cancer. JCO Precis Oncol PO. 2017;17(1):1–13. doi: 10.1200/PO.17.00063
  • Facchinetti F, Friboulet L. Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date. Lung Cancer. 2019;10:87–94. doi: 10.2147/LCTT.S190786
  • Han J, Xu Y, Zhou, Y, et al. The effect of TKI therapy and chemotherapy treatment delivery sequence on total progression free survival in patients with advanced EGFR-mutated NSCLC. Oncol Lett. 2020;20(1). doi: 10.3892/ol.2020.11535

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.